Combination Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
(NeoCOAST-2 Trial)
Trial Summary
What is the purpose of this trial?
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
Do I need to stop my current medications to join the trial?
The trial does not specify if you need to stop your current medications, but you cannot use immunosuppressive medication within 14 days before starting the study. It's best to discuss your current medications with the trial team.
What data supports the effectiveness of the drug combination chemotherapy and immunotherapy for non-small cell lung cancer?
Research shows that combining pemetrexed with platinum-based drugs like cisplatin or carboplatin improves survival in non-small cell lung cancer patients. Additionally, adding pembrolizumab, an immunotherapy drug, to this combination further enhances survival rates, regardless of specific tumor characteristics.12345
Is the combination of chemotherapy and immunotherapy for non-small cell lung cancer safe?
The combination of pemetrexed with cisplatin or carboplatin has been studied for safety in non-small cell lung cancer patients. Common side effects include fatigue, nausea, and blood-related issues like neutropenia (low white blood cell count). Some serious side effects, such as skin reactions, have been reported, but taking vitamins and steroids can help reduce these risks.16789
How is the combination chemotherapy and immunotherapy treatment for non-small cell lung cancer different from other treatments?
Eligibility Criteria
This trial is for newly diagnosed NSCLC patients with resectable disease stages IIA-IIIB, who have good organ and bone marrow function, can provide recent tumor samples to check certain biomarkers, and have a performance status of 0 or 1. It excludes those with autoimmune disorders, prior cancer treatments, planned lung surgeries like pneumonectomy, EGFR mutations/ALK translocations, heart issues including QTcF ≥470 ms, previous immune therapy or specific ADCs use.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Neoadjuvant Treatment
Participants receive neoadjuvant treatment with various combinations of Durvalumab, Oleclumab, Monalizumab, Volrustomig, Rilvegostomig, AZD0171, Dato-DXd, and chemotherapy
Surgery
Participants undergo surgical resection of the tumor
Adjuvant Treatment
Participants receive adjuvant treatment with various combinations of Durvalumab, Oleclumab, Monalizumab, Volrustomig, Rilvegostomig, AZD0171, and Dato-DXd
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Carboplatin (Chemotherapy)
- Cisplatin (Chemotherapy)
- Dato-DXd (Antibody-Drug Conjugate)
- Durvalumab (Monoclonal Antibodies)
- MEDI5752 (Monoclonal Antibodies)
- Monalizumab (Monoclonal Antibodies)
- Oleclumab (Monoclonal Antibodies)
- Paclitaxel (Chemotherapy)
- Pemetrexed (Chemotherapy)